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Excessive analgesic consumption has been recognized as a
very important contributing factor in the development of
chronic renal disease, an expensive health care problem that
will be better controlled by curbing the abuse of these drugs and
improving the therapeutic management of patients [I]. There is,
however, still an urgent need to understand the molecular
processes that underlie the development of medullary damage
and the pathogenesis of its secondary consequences if we wish
to optimize therapy for analgesic abusers and ensure that safer
analgesic and anti-inflammatory medications will he available in
the future. The risk of medullary damage may also extend to
several groups of chemicals (to which man is exposed environ-
mentally) that are not classed as analgesics or non-steroidals,
and there is a need to establish the risk that these agents pose to
human health.
Development and course of analgesic-associated nephropathy
Renal papillary necrosis (RPN) was first observed as an
iatrogenic lesion associated with the long-term abusive con-
sumption of mixed analgesics (especially those containing
phenacetin) over 30 years ago [2]. Since then, several thousand
patients have presented with RPN [3], and many have devel-
oped secondary degenerative changes such as end-stage renal
disease (ESRD) or upper urothelial carcinoma (UUC), various
aspects of which have been reviewed [3—71. Typically, the renal
changes follow a multistage degenerative pathology. The earli-
est damage includes necrosis of the fine elements of the
medulla, such as the capillaries, the thin loops of Henle, and the
interstitial cells. Then, progressively the covering epithelium,
the collecting ducts, and the ducts of Bellini undergo necrosis.
Secondary degenerative changes occur in the renal cortex when
the entire medulla is damaged. These include tubular dilatation,
hyaline casts, tubular and glomerular sclerosis, pyelonephritis,
fibrosis, and scarring [8. 9]. Eventually, the marked loss of
functional nephrons leads to ESRD [3, 4, 6, 7]. Other histopath-
ological changes include extensive deposits of lipid material in,
and loss of the extracellular mucopolysaccharide matrix from,
the medulla, calcification of dead tissue, and capillary sclerosis
[8—Il]. Another common sequel to papillary damage is
urothelial hyperplasia[l2], and it is not uncommon for analgesic
abusers to develop upper urothelial, ureteric, or bladder carci-
noma, although this may take 10 to 20 years to become apparent
clinically [13, 14]. In addition to these pathological abnormali-
ties there are a number of clinically important renal functional
changes. These include urine concentration and acidification
defects [15], sodium, calcium, and other electrolyte wastage [16,
17], and bone changes [18]. These marked functional changes
only occur when the degenerative pathology is advanced, but
none are in themselves pathognomonic for RPN. It is most
difficult to diagnose RPN at an early and possibly reversible
stage [7], although at an advanced stage the lesion is distinctive
radiologically [3—7, 19]. In the absence of a definitive diagnostic
criteria for the early diagnosis of either the presence or severity
of this lesion, it has not been possible to establish with certainty
which single analgesic (or what combinations of analgesics)
cause RPN in man, nor to define accurately the total quantity of
each compound that had to be consumed to produce a papil-
lotoxic effect. Typically, however, phenacetin, acetaminophen
(paracetamol), and aspirin combinations taken over 3 to 45
years in quantities of 2 to 44 kg have been estimated to favor a
substantial likelihood of RPN developing [3—7]. This very large
range precludes accurate clinical predictions and despite an
extensive and intense program of research over the last 30
years, many aspects underlying the etiology of RPN, its pro-
gression to ESRD, and the relationship between RPN and UUC
remain obscure [7]. Animal models offer a potentially important
means by which to understand the pathomechanism of RPN and
provide a model system to improve the early diagnosis of the
lesion to identify which analgesic(s) have the greatest papil-
lotoxic potential and what factors exacerbate its development
or contribute to the secondary consequences of papillary dam-
age. The aim of this commentary is to compare and contrast the
experimentally induced models with the clinically relevant
lesion, to examine the validity of using animal models to
provide a deeper understanding of RPN in humans (and also the
development and course of ESRD and UUC), and also to
suggest those areas of research that may yield clinically signif-
icant data in the future.
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Spontaneously occurring and non-chemically induced RPN
in animals
RPN has been reported to develop spontaneously in associ-
ation with amyloidosis in cats and mice, and also in aging mice
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[20—22]. Amyloid-associated RPN is apparently uncommon in
humans, and very few experimental investigations have been
undertaken in these cat and mice models. Furthermore, an
understanding of these spontaneous lesions will probably not
help to explain the pathology of analgesic-associated RPN
because the deposit of amyloid will complicate a clear interpre-
tation of the molecular nature of this type of papillary lesion in
animals.
The Gunn rat, a mutant strain of Albino rat with a recessive
trait for hyperbi[irubinemia develops RPN progressively with
age, a series of changes that has been studied extensively
[23—28]. The administration of certain analgesic preparations,
most notably aspirin and several non-steroidal anti-inflam-
matory drugs (NSAIDs), but not phenacetin or acetaminophen,
has been shown to exacerbate the spontaneous development of
RPN in the Gunn rat [25, 261. Many of the renal functional and
morphological changes seen in the Gunn rat model, such as
papillary necrosis, loss of urine concentrating ability, and
secondary cortical changes (once the medulla has undergone
necrosis) are similar to chemically induced RPN [26, 27]. The
pathogenesis of RPN in this abnormal strain of rat has been
considered [7, 23—28], but the marked number of extrarenal
lesions that also develop as a result of their inability to
conjugate bilirubin suggests that this model may be inappropri-
ate to understanding analgesic- and NSAID-associated RPN
[7].
The intravenous injection of human serum produces a mcd-
ullary necrosis in rats, the mechanism of which is not under-
stood, although it has been the subject of several investigations
[29—311. Similarly, occluding the renal artery or venous blood
supply, or the ligation of the ureter, have been reported to cause
a medullary lesion [32—35J. In common with serum-induced
RPN, however, these models may be inappropriate because
necrotic damage affects the outer medulla, whereas the papil-
lary tip is the focus of damage in the chemical models. RPN also
develops in rats that have been maintained on a fat-free diet for
a prolonged period [36, 37]. The renal papilla is not, however,
the only tissue to show pathology and other organs are grossly
abnormal also. Abscission of the papilla tip has also been
achieved surgically, but most procedures have used an incision
through the cortex following arterial clamping [38]. Under these
circumstances, it is difficult to separate the renal changes
associated with the ablation of the papilla from those caused by
transient anoxia and surgical damage and scarring of the cortex.
Hardy [39] has developed an atraumatic technique for papil-
lectomy which, in itself, causes almost no renal functional and
histopathological changes. In general, there is a paucity of data
on the morphological changes and the functional derangement
that are associated with these non-chemically induced lesions
[20—39], but it seems probable that these models have little
relevance to analgesic- and NSAID-associated renal papillary
necrosis because they affect the outer medulla or cause gross
extramedullary effects.
Chemically induced RPN
A large number of analgesics, NSAIDs and their structural
analogues, and a variety of other chemicals (Table 1) have been
shown to cause renal papillary necrosis when administered
either on a chronic, sub-chronic, or acute dosage regimen [3—7,
39—56]. Several of these compounds appear to be highly selec-
Analgesic mixtures
Aspirin, antipyrine (phena-
zone), and caffeine ____________________________
Aspirin, phenacetin, and
codeine
Aspirin, phenacetin, and
caffeine
Aspirin and pentazocine
Non-steroidal
anti-inflammatory
Alclofenac
Benoxaprofen
Fenoprofen
Flufenamic acid
Glafenine
Ibuprofen
Indomethacin
Ketoprofen
Meclofenamic acid
Mefenamic acid
Naproxen
Oxyphenbutazone
Phenylbutazone
Tolfenamic acid
Zomepirac
Data from [3—7, 39—58, 64—671 and unpublished observations.
tive and destroy only the renal medullary tissue, while other
compounds may also produce cortical or extrarenal lesions.
These papillotoxic agents can, for the sake of convenience, be
divided into compounds that are related to the analgesics,
NSAIDs (or their structural analogues), and those that are not.
Before considering the two groups of papillotoxins, it is essen-
tial to comment on some of the problems that have pervaded the
study of RPN in animals.
Irreproducible and variable animal models of RPN
In the past, it has often been difficult to study animal models
of RPN and to interpet research data because of irreproducible
or variable lesions and other complicating factors. First, some
animal species or strains may be more resistant to RPN, but
several early publications (see 3, 4, 6 for references) failed to
define essential factors, such as the purity of the compound
used, the route of administration, the sex and strain of the
animals, and the environmental and dietary conditions under
which they were kept. Thus, there is very little data on species
sensitivity. There is also a confusing use of the terminology to
describe renal pathology, often without adequate information to
define the type of lesion [3, 7]. Second, it appears that there has
often been difficulty in reproducing lesions in experimental
animals, especially using the analgesics and some NSAIDs [3,
Table 1. Analgesics, NSAIDs, their non-therapeutically used
analogues, and other drugs and chemicals implicated with causing a
direct papillotoxic effect
Analgesics
Acetaminophen (para-
cetamol)
Aminopyrine
Antipyrine (phenazone)
Aspirin
Phenacetin
Other therapeutic agents
5-Aminosalicylic acid
Cyclophosphamide
Dapsone
Dextropropoxyphene
Phenothiazine
Radio contrast media
Analgesic and non-steroidal
anti-inflammatory drug analogues
and metabolites
Para-aminophenol
Diphenylamine
Diphenyl
Diphenylmethylalcohol
4-Isopropylbiphenyl
Para-phenetidine
N-Phenylanthranilic acid
Phenylalkanoic acid
Chemical agents
2-Bromoethanamine hydrobromide
3-Bromopropanamine
hydrobromide
2-Chloroethanamine hydrochloride
2-Chloro-N ,N '-dimethylethanamine
Ethyleneimine
Jet fuel petroleum
Mono-N-methylaniline
Polychionnated biphenyl
Propyleneimine
Tetrahydroquinoline
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7] due to a number of variables that have not yet been
adequately identified or controlled. This may include prepara-
tion of the papillotoxin dosage regimen, diet, and availability of
water, among other factors. Third, although some compounds
cause RPN acutely, in general, it takes many months of dosing
with analgesics or NSAIDs to induce papillary necrosis in
animals. The high-dose, long-term administration of these com-
pounds (particularly the NSAIDs) has often resulted in a large
number of fatalities due to extrarenal toxicity such as gastric
ulceration [3, 7, 57]. There have been examples where the
development of RPN has been exacerbated by dehydrating the
animals before or during the course of dosing [2, 7, 40]. It must,
however, be stressed that even when RPN is successfully
induced by chronic exposure there is always a substantial
degree of biological variability. This is reflected by a lesion that
varies from minimal to an extensive papillary necrosis with
secondary cortical changes in a single group of animals exposed
to identical regimen and for the same duration [39—41, 46—52].
This variability serves to obfuscate the detailed sequence of
time-course changes and obscures the statistical difference
between treated and control groups [581. The development of
RPN is, even under the most ideal circumstances, silent, and
there are no chemical markers in blood or urine, nor are there
any other established non-invasive criteria by which to differ-
entiate either the presence of papillary damage or its severity
[3—7, 40—54]. The loss of urine concentrating ability is not
sensitive [58] nor is it pathognomonic for RPN and may, in fact,
be a consequence of an extrarenal lesion or, more frequently, a
variety of other renal insults that do not damage the morpholo-
gy of the medulla. All diuretic agents will produce a transient
loss of concentrating ability and many chemicals that damage
the cortex, such as potassium dichromate [59], fluoride, fluor-
inated anesthetics, corticosteroids, aminoglycosides, lithium
[601, and halogenated solvents [611 all cause a polyuria. Thus,
the diagnosis of experimentally induced RPN must depend on
histopathology. Resorting to this terminal technique of histol-
ogy cannot, on its own, facilitate those investigations that
attempt to follow the onset of RPN, the recovery following
cessation of insult, or any change in the course of the lesion as
a result of "therapeutic intervention" due to the very marked
inter-animal variability. Histopathology may also miss focal
lesions [41, 45] and often an apex-limited lesion undergoes
abscission from the rest of the medulla, which then
re-epithelializes. The remaining medullary stump may appear to
be a normal (but obliquely) sectioned tissue during a routine
investigation [41]. Thus, successful histopathological identifica-
tion of the lesion necessitates painstaking attention to cutting
serial sections to find the papillary apex. There is at least one
example where these exacting procedures have not been fol-
lowed, and an underlying RPN has only been reported in terms
of a secondary cortical lesion. Diphenylamine is widely used to
produce a model cystic renal lesion [62, 63], but the first
change associated with this compound is RPN, and it is only
later that extensive tubular dilatation occurs [39] (Ci Powell,
JW Bridges, and PH Bach, unpublished observation, 1984).
Analgesic- and NSA ID -associated RPN
The administration of analgesics and NSAIDs has not been
uniformly successful in producing RPN in experimental animals
[3—7]. Mixed analgesics, associated with water deprivation,
exacerbate the development of RPN [40], but the toxic potential
of individual analgesics remains most controversial. Some
workers have shown that amidopyrine [46], antipyrine [46], and
aspirin [47] on their own cause RPN, but this has not been
reproducible [3, 6, 7]. There are very few examples where
acetaminopen (paracetamol) or phenacetin have [3—7, 40, 48],
on their own, caused RPN. NSAIDs present a different picture
where those N SAID compounds (and analogues) listed in Table
1 have caused RPN in at least one experimental species [3—7,
64-66]. Depending on the species, dose, route, and so forth,
these compounds may cause RPN over a period of repeated
dosing for up to 90 days, but with NSAIDs have a propensity to
cause extrarenal lesions in rodents, as a result of which there
may be many fatalities before frank renal lesions have devel-
oped [3, 7, 57]. The development of NSAID-induced RPN also
shows a great deal of variability and may be irreproducible and,
as explained above, might easily be missed at necropsy. The
biphenyl analogues of the fenamate NSAIDs such as
N-phenylanthanilic acid and diphenylamine cause RPN sub-
acutely [39, 41, 58] (Ci Powell, iW Bridges, and PH Bach,
unpublished observation, 1984), with a few extrarenal effects.
Compounds without analgesic- or NSAID-like effects
A variety of compounds including mono-N-methylaniline
[49], tetrahydroquinoline [50], jet fuel petroleum [51], and
Arochlor 1242 (a polychlorinated bi-phenyl) [52] have been
reported to cause RPN, Very little is known, however, about
the time-course changes or the mechanism by which any of
these compounds cause the lesion. By far, the most widely
studied papillotoxins are ethyleneimine (El) [7, 53, 54], 2-
bromoethanamine (BEA) hydrobromide [7, 42—45, 67—70] and
their analogues [55, 56]. A single dose of either El or BEA
causes RPN in all animals within a matter of days. The
pathophysiological course for the development of the RPN
caused by El [7] and BEA [7, 44] have been reviewed in detail,
and the most important conclusions from these models will be
considered below.
Comparison of acutely, sub-chronically, and chronically
induced RPN
One of the generally accepted axioms of experimental medi-
cine is that the greater the concurrence between the
pathophysiology of a model lesion and that which occurs in
humans the more likely will experimental observations be
related to an interpretation of clinical significance. The chemi-
cally induced models of RPN resemble the syndrome described
in analgesic abusers [3—7, 44], and any attempt to use these
similarities to understand the molecular pathogenesis of RPN in
humans demands a careful validation of the animal models.
Comparison of pathological changes associated with different
types of chemically induced RPN
The sequence of pathological changes in the development of
experimentally induced RPN are essentially similar when the
acutely induced lesion, the sub-chronically induced model,
chronically induced changes, and the pathological findings in
human analgesic abusers are compared (Table 2). There are,
however, some minor differences between these "classes" of
RPN. The lack of an inflammatory response in the acutely
Yes
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Yes
No
Yes
Yes
Increase then loss
Yes
No
Yes
Yes
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No data
Yes
Yes
No
Yes
Yes
Yes
No
After salt loading or
arterial clipping
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Yes
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Yes
Yes
Yes
Yes
Loss
Yes
Yes
Yes
Yes
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Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Increase or loss
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Common
Common
induced models [7, 42—45] may represent the rapidity with
which the lesion develops, as a result of which the
microvascularity is lost and inflammatory infiltrates cannot
reach the damaged tissue. Urothelial hyperplasia is common
following chemically induced RPN [7, 41—56. 58, 65], but the
absence of malignant changes in the animal models possibly
reflects a failure to extend these experiments for a significant
period of time, or it reflects a multistage lesion where RPN
represents only one facet (see 7 for review). It is not yet
possible to explain all of the differences between these models,
but these apparent discrepancies could be due to inadequate
experimental data.
Comparison of the junctional changes associated with
diJfrrent types of chemically induced RPN
The renal functional changes in the different animals models
of RPN and in humans are also strikingly similar (Table 2).
These included a urine concentrating and acidification defect,
electrolyte wastage, progressive loss of renal function, and an
increased propensity to develop urinary tract infection (UT!)
[70, 711. The failure of rats to develop calculi may be related to a
different dietary load of cations or the relative difficulty of
inducing calculi in rats 172]. Both humans 1161 and rats [67—691
with RPN have a significant sodium chloride and electrolyte
wastage, which may decrease the likelihood of hypertension.
BEA-treated rats do, however, show an increased blood pres-
sure, especially following sodium loading and renal artery
manipulation [73—75 1.
In summary, the pathology and the renal functional changes
are very similar when each of the three different classes of
chemically induced models for RPN are compared in animals.
and all of these model lesions match the changes seen in
analgesic abusers. This does not, of necessity, mean that a
similar mechanism causes RPN in each model. It does, how-
ever, suggest that there are at least some common pathways in
the sequelae of events that lead to RPN and some of its
secondary changes. Thus, while it may not be reliable to
extrapolate from an acute animal model directly to human
beings, it is likely that an understanding of the pathophysiolog-
ical changes in an acute model of RPN will give a better insight
into the chronically induced models, from which the molecular
pathogenesis of the lesion that occurs in humans could be
defined more clearly.
Mechanism of RPN
If animal models are to promote an understanding of the
lesion in humans they must serve either to support or repudiate
the hypotheses that have been proposed to explain the molec-
ular pathogenesis of RPN [3—7, 44, 76—79]. It is important to
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Table 2. Comparison of pathological changes in experimentally induced renal papillary necrosis and the lesions found in humans
Type of renal papillary necrosis
Chronically induced
Acutely induced (Analgesics, NSAIDs, and Analgesic-associated
Morphological and functional changes (BEA and El) NSAID analogues) lesion in humans
Earlya
Papilla apex primary site of lesion
Loss of thin loop of Henle and interstitial cells
Loss of vasa recta
Extends to include outer medulla but not beyond
corticomedullary junction
Microvascular occlusion
Loss of concentrating mechanism
Intermediate°
Loss of collecting ducts and covering epithelia
Changed staining of extracellular matrix
Fatty changes
Inflammatory response
Epithelial hyperplasia
Regeneration and re-epithelialization
Calcification
Renal and bladder calculi
Urinary tract infection
Hyperplasia of transitional urothelia of relvis. ureter, and/or
bladder
Acidification defect
Electrolyte wastage
Total or Late
Secondary cortical changes overlying necrosed papilla, for
example, scarring
Cystic dilatation
Carcinoma of transitional urothelia of pelvis, ureter, and bladder
Hypertension
Data from [3—12, 15—18, 41—58, 64—69, 73—75, 79) and unpublished observations.
a The criteria of early, intermediate, and total necrosis are based on the definitions used by Burry (8, 91.
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emphasize that it is impossible to study the detailed progression
of the pathophysiology associated with RPN in humans because
of the advanced stage at which it is normally diagnosed, but the
sequence of change can be more fully evaluated using the
various animal models that have been described above.
Counter—current concentration
The role of counter-current concentration in delivering a
toxic level of "papillotoxin" to the medulla (but not the cortex)
appears to be supported for several analgesics (for example,
acetaminophen and aspirin) [78, 79], but closer examination of
the available data suggests that there are a number of anoma-
lies, including the distribution of aspirin (which is localized
within the nephron) [79] and antipyrine (which is apparently
present in higher concentrations in the cortex) [801. These and
other data suggest that active urine concentration may be an
important toxicokinetic factor, but does not explain the
toxicodynamics or molecular mechanism that underlie the
lesion.
isehetnic injury
Whereas microvascular degeneration and medullary
ischemia have been strongly favored as the pathophysiological
change that explains the focal nature of this lesion [3—7, 44,
76—79], microvascular occlusion is not a prerequisite for the
acutely induced lesion [45]. Vascular changes do, however, in
common with those seen in humans [II], occur during the more
advanced stages of all chemically induced lesions [7, 47] (Ci
Powell, JW Bridges, and PH Bach, unpublished observations,
1984). Unfortunately, the variability in the development of the
lesion that has been induced sub-acutely and chronically has
made it most difficult (if not impossible) to separate the micro-
vascular changes from the other degenerative pathology. Thus,
it is impossible to be certain if microvascular changes are the
primary pathological event that precede RPN, if they run
parallel with, or if they follow medullary necrosis.
inhibition of prostaglandin synthesis
There is some evidence to suggest that the inhibition of
prostaglandin (PG) synthesis relates closely to the papillotoxic
potential of a series of analgesics, NSAIDs, and their analogues
[3—7, 76, 77]. It must, however, be stressed that the perturba-
tion of the renal system may be exceptionally complex and
factors other than the inhibition of PGE2 synthesis may be
involved in the development of RPN [7, 811.
inter,nediary metabolism
At present, there is very little data from animal models to
support the concept that disrupting intermediary metabolism
plays an important role in the development of RPN [3, 7, 76,
77]. There are, however, a variety of other metabolic processes
that occur in the medulla, such as lipogenesis [82], proteoglycan
and glycosaminoglycan synthesis [83, 84], which could also be
affected adversely. Analgesics and NSAIDs depress lipogenesis
[85] and matrix synthesis [86] in other tissues.
immunological changes
There is no evidence to suggest that immunological changes
are causally associated with the induction of the acute lesion in
animals [87] or chronic lesion in humans [881.
AA
I Fatty
ac1
O
oxygenase
PGG2 Carcinogen
analgesiciNSAlD
PG hydroperoxidase
BRI
Add uct
LPO
TBX
GSH
Inactive
Fig. 1. Schematic representation for prostaglandin synthesis and the
prostaglandin hydroperoxidase mediated co-oxidative activation of
non-steroidal anti-inflammatory drug analgesics and carcinogens, and
the generation of free radicals via lipid peroxidation. Abbreviations
are: AA, arachidonic acid; Adduct, adduct formed between a reactive
intermediate and a macromolecule such as a protein or nucleic acid;
BRI, biologically reactive intermediate; GSH, glutathione; LPO, lipid
peroxidation; NSAID, non-steroidal anti-inflammatory drug; PG, pros-
taglandin; TBX, thromboxane.
Metabolic activation
Over the last decade, the role of the metabolic activation of
chemicals to reactive intermediates, which injure cells, has
become very important. Cytochrome P-450-mediated activation
of a large number of chemicals is associated with lesions in the
liver, lungs, testes, and other organs because of the large
quantities of this enzyme system located in these tissues [89].
There is, however, a sparsity of Cytochrome P-450 in the
cortex, and the medulla has no detectable P-450 activity [90].
Originally, it was thought that P-450 was responsible for the
metabolic activation of phenacetin to the "ultimate" papillo-
toxin [91], but if such a reactive intermediate did cause RPN, it
would have to be formed in the cortex (or extrarenally) and
then reach the medulla. Based on the highly reactive nature of
these products, it is more likely that they are generated in the
tissue that is damaged.
Recently, there has been a growing interest in the role of
co-oxygenation of exogenous chemicals associated with the
bioconversion of arachidonic acid. The available evidence
suggests that this type of metabolic activation of chemicals is
associated with PG hydroperoxidase (Fig. I), when PGG2 is
converted to PGH2 [92]. This mechanism is exceptionally
attractive because of the significant quantities of PG synthetase
activity in the medulla, but at present it has only been related to
the metabolic activation of acetaminophen [931 and
para-phenetidine [94] (the major deacetylated metabolite of
phenacetin). Neither of these compounds (on their own) have a
propensity to cause renal papitlary necrosis in experimental
animals [3, 7, 40, 48], and their role in RPN is not proven in
humans. It has, therefore, been assumed that a synergistic
interaction between mixed analgesics greatly increases papil-
lotoxicity [77]. Recently, a hypothesis has been put forward to
explain how the administration of aspirin, together with
acetaminophen or phenacetin, could be involved in the syner-
gistic activation of these compounds [81] particularly because
Other PG
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of the limited levels of glutathione in the medulla [951. In
addition, the formation of reactive intermediates would proba-
bly generate a significant degree of lipid peroxidation in the
medulla, which is rich in polyunsaturated fatty acids [96].
Normally, in the cortex and extrarenal tissue higher levels of
glutathione protect the cell from alkylating agents and lipid
peroxidation [97]. At this time, however, it is not certain that
metabolic activation of analgesics or NSAIDs has any signifi-
cance to the pathogenesis of RPN, although the formation of
reactive chemicals is thought to have a central role in many
chemically induced necroses [89] and carcinomas [981.
In summary, it has not yet been possible to develop a single
unifying hypothesis to explain the development of RPN in
humans or even in the animal models, but much of the available
data does suggest that several different mechanisms may func-
tion in concert to cause an interplay of pathophysiological
changes that lead to RPN. At present, the most likely factor
appears to be the oxidative generation of reactive intermediates
of the offending chemicals and the absence of adequate protec-
tive mechanisms to prevent medullary damage.
What have we learned from animal models in relation to the
development of RPN in humans?
Animal models have established several important patho-
physiological processes in the development of RPN and offer
some insight into the pathogenesis of the secondary sequelae.
All of the animal models, together with the lesion that occurs in
humans, have in common the development of necrotic changes
from the apex of the papilla, which affects the fine elements first,
then all other anatomic parts of the medulla [3—7, 40—56, 67—69].
Concomitantly, there is a loss of concentrating power (when the
fine elements of the medulla are damaged), and there is exten-
sive electrolyte wastage in animals [44, 67—69] and in humans
[16], which may contribute to the calcification of medullary
tissue that has been damaged [41, 47, 79]. Once the papilla has
been necrosed, the kidney is more susceptible to bacterial
colonization in animals [70, 71], a factor that could, in humans,
contribute to the degenerative changes associated with pyelo-
nephritis. The combination of electrolyte wastage, calcification
of dead tissue, and UTI in animal models provides a combina-
tion of pathophysiology that may explain the high incidence of
urinary calculi that have been reported in some analgesic
abusers [8—10, 19, 99]. The animal models show that secondary
cortical changes, such as nephron dilatation and subsequent
degeneration, are secondary to the destruction of the medullary
apex [7, 39, 41, 45—48, 58]. The loss of the medulla, and possibly
other secondary changes in the cortex, may be important in
causing hypertension in animals, especially if the control of
blood pressure is perturbed [72—74], and this may be highly
relevant to an increased blood pressure in humans [3—7].
Most of the available data supports the important role of
toxicokinetics in the delivery of papillotoxic compounds to the
kidney [5, 7], and suggests that the active concentration of urine
makes kidneys more sensitive to these chemicals [3—7, 9, 40,
44]. More important, the use of animal models has shown that
most (if not all) analgesics, non-steroidal anti-inflammatory
drugs, their analogues, plus an exceptionally large variety of
other chemicals (many of which [39—45, 49—56, 64, 67—70] have
widespread industrial use and/or occur as environmental con-
taminants), have the potential to cause RPN. Thus, it may be
shortsighted to believe that only acetaminophen, phenacetin, or
mixed analgesics cause RPN. At least some of the lesions
encountered clinically could be related to compounds other
than analgesics.
Animal models can tell us still more
Animal models can continue to provide us with exceptionally
valuable information on those aspects of the molecular pathol-
ogy of RPN that cannot be gained from studying human
patients. The most urgent need is to develop sensitive and
specific non-invasive means of identifying renal papillary necro-
sis in model systems. Obviously, the successful implementation
of a diagnostic technique for RPN would have immediate
applications to those humans at risk of developing the lesion
through therapeutic necessity or abusive exposure. A non-
invasive means of assessing the severity of RPN is a prerequi-
site to understanding the primary mechanism of the lesion and
which factors may exacerbate or ameliorate its development
and alter its course; the role of RPN in the development of
UUC, the relationship between each of the analgesics and the
risk of developing either RPN and/or UUC, and how new
chemicals (particularly medicinal preparations) should be eval-
uated for their papillotoxic potential.
In the past, differences between animal strains and species
have been widely exploited to study the pathogenesis and
treatment of hypertension [100], diabetes [101], and the immu-
nological basis of protection against infection [102], among a
host of other factors. It may also be possible to exploit the
apparent different responses of animals to a papillotoxin. The
identification of resistant and sensitive strains (sub-strains or
species) could provide better animal models, where once we
understood the molecular basis for a genetically determined
sensitivity it should be possible to identify those humans who
are likely to be at a higher risk of developing RPN. There is
already evidence to show that the homozygous Brattleboro rat
is unaffected by a dose of BEA that causes RPN in the
heterozygotes and other rats [44, 69]. This adds credence to the
concept that active urine concentration exacerbates the devel-
opment of RPN. The actual mechanisms may be more complex,
because hamsters require twice the dose of BEA given to
Wistar rats to cause a similar RPN, despite the fact that both
species produce a highly concentrated urine, that is, 2500 to
3000 mOsm/kg (B. Schmidt-Nielsen, unpublished observation,
1984). C57BL/6 mice metabolize phenacetin much the same as
humans, and they are also one of the few species to develop
phenacetin-induced RPN [48]. Different rat strains are also
known to respond uniquely to NSAID challenge [65], but none
of these data has been studied systematically. A great deal
might also be gained from studying the biological basis of
inter-rat variability, the reduction and improved control of
which would allow us to compare single and mixed analgesics,
NSAIDs, and establish the papillotoxic potential of each com-
pound. Less variability would also make it easier to assess
which dietary, environmental, therapeutic, or other factors
could exacerbate or ameliorate the development of RPN and
the progression to either of ESRD or UUC.
At least two major advances would be accrued from progress
in the research avenues that have been suggested. First, it will
establish the papillotoxicity of each analgesic and NSAID, their
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potential to interact, and what factors exacerbate the develop-
ment of RPN and alter its secondary course—data that are
essential to the clinical situation and the design of epidemiolog-
ically valid studies. Second, an understanding of the molecular
mechanism of RPN will provide a scientific basis upon which to
chose an appropriate animal species to undertake the chemical
safety evaluation of new analgesics and NSAIDs, to design
safer drugs, and to implement a rational approach to therapeutic
intervention when RPN is at an early stage (where changes may
still be reversible), and it may also be possible to prevent the
degenerative course of RPN to ESRD or UUC.
Conclusion
The appropriate use of animal models holds a very important
key to understanding the genesis of RPN and its progression to
ESRD or UUC. It will be some time before the mechanisms
underlying these animal models are explained fully, but it is
only when this has been accomplished that the safety of those
analgesics and NSAIDs that are readily available and widely
used (and other chemicals to which humans are exposed) can be
evaluated satisfactorily and safer drugs produced. Further-
more, the use of animal models may provide a rational basis by
which to prevent the secondary degenerative changes that
invariably plunge analgesic abusers into chronic renal failure or
urothelial carcinoma. There is still a strong case to be made for
the continued intensive evaluation of the pathology, functional
changes, and the biochemical events that are associated with
the induction of RPN in model systems using analgesic/NSAIDs
and those other chemicals that cause an experimentally repro-
ducible model of papillary necrosis.
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